NCT01838655View on ClinicalTrials.gov

Nitisinone for Type 1B Oculocutaneous Albinism

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 16, 2013

Primary Completion Date

July 11, 2016

Study Completion Date

February 7, 2017

Conditions
AlbinismVision Loss
Interventions
DRUG

Nitisinone

Oral dose of 2mg daily for 12 months.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Human Genome Research Institute (NHGRI)

NIH

lead

National Eye Institute (NEI)

NIH

NCT01838655 - Nitisinone for Type 1B Oculocutaneous Albinism | Biotech Hunter | Biotech Hunter